- Home
- RBCAA vs KNSA Comparison
RBCAA vs KNSA Comparison
Compare RBCAA & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBCAA
- KNSA
- Stock Information
- Founded
- RBCAA 1974
- KNSA 2015
- Country
- RBCAA United States
- KNSA United Kingdom
- Employees
- RBCAA N/A
- KNSA N/A
- Industry
- RBCAA Major Banks
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- RBCAA Finance
- KNSA Health Care
- Exchange
- RBCAA Nasdaq
- KNSA Nasdaq
- Market Cap
- RBCAA 1.2B
- KNSA 1.5B
- IPO Year
- RBCAA 1998
- KNSA 2018
- Fundamental
- Price
- RBCAA $64.09
- KNSA $20.21
- Analyst Decision
- RBCAA
- KNSA Strong Buy
- Analyst Count
- RBCAA 0
- KNSA 6
- Target Price
- RBCAA N/A
- KNSA $37.17
- AVG Volume (30 Days)
- RBCAA 38.7K
- KNSA 638.0K
- Earning Date
- RBCAA 04-28-2025
- KNSA 04-29-2025
- Dividend Yield
- RBCAA 2.82%
- KNSA N/A
- EPS Growth
- RBCAA 12.83
- KNSA N/A
- EPS
- RBCAA 5.14
- KNSA N/A
- Revenue
- RBCAA $330,428,000.00
- KNSA $423,239,000.00
- Revenue This Year
- RBCAA $1.56
- KNSA $37.21
- Revenue Next Year
- RBCAA $3.87
- KNSA $2.58
- P/E Ratio
- RBCAA $12.44
- KNSA N/A
- Revenue Growth
- RBCAA 6.29
- KNSA 56.60
- 52 Week Low
- RBCAA $46.83
- KNSA $16.56
- 52 Week High
- RBCAA $80.68
- KNSA $28.15
- Technical
- Relative Strength Index (RSI)
- RBCAA 52.98
- KNSA 44.56
- Support Level
- RBCAA $59.08
- KNSA $18.26
- Resistance Level
- RBCAA $63.70
- KNSA $21.24
- Average True Range (ATR)
- RBCAA 2.96
- KNSA 1.12
- MACD
- RBCAA 0.25
- KNSA -0.12
- Stochastic Oscillator
- RBCAA 86.49
- KNSA 44.43
About RBCAA Republic Bancorp Inc.
Republic Bancorp Inc operates as a financial institution that provides both traditional and non-traditional banking products through five reportable segments. It has traditional banking which generates the majority of revenue, Warehouse Lending, Tax Refund Solutions (TRS), Republic Payment Solutions segment, and Republic Credit Solutions (RCS) business segments. The business activities of these segments include retail mortgage and commercial lending, construction and land development lending, internet lending, correspondent and indirect lending and also private banking, treasury management services, internet, and mobile banking, bank acquisitions, short-term revolving credit facilities, fixed-term residential real estate loans and receipt and payment of federal.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.